

You make the choice, clinical decision making in diabetes: Use of GLP-1 receptor agonists in clinical practice

CME certificates

To apply for *AMA PRA Category 1 Credit(s)* or AOA Category 1-A CME credits online, log-in to <http://elseviercme.com/910483>. Upon successful completion of the evaluation form and posttest, you can download and print your certificate of CME credit; AOA credit will be sent to participants from ACOFP. You can also fax this completed evaluation form and posttest to +1 877 771 9237, email to elsevierCME@elsevier.com, or mail to:

Elsevier Office of Continuing Medical Education
Department 910483
P.O. Box 265
Pipersville, PA 18947

Program overview

This informative and evidence-based program will challenge osteopathic family physicians and other healthcare professionals on their knowledge and practice related to the care of patients with diabetes. The use of new glucose-lowering treatment strategies such as incretin-based therapies will be discussed. Understanding of current therapeutic options will also be discussed.

This supplement will review GLP-1 RAs, with not only their glycemic lowering abilities, but also their pleiotropic effects on weight and cardiovascular risk factors. Additionally, it will include a review of evidence from clinical trials supporting their use as part of combination therapy. In closing, this supplement will help osteopathic family physicians and other healthcare professionals develop T2DM treatment strategies and discuss how to incorporate them successfully into patient care.

Target audience

This enduring material is intended for physicians, osteopathic family physicians, physician assistants, and nurse practitioners involved in the management of patients with type 2 diabetes (T2DM).

Learning objectives

After participating in this educational activity, learners should be better able to:

1. Diagnose diabetes and select therapy for patients early in the course of disease
2. Identify patients who would benefit from GLP-1 RA therapy and those for whom it may not be appropriate
3. Explain to patients the efficacy, safety, and tolerability of GLP-1 RAs
4. Develop appropriate combination therapy strategies and adjust doses of existing agents if needed

5. Differentiate for patients GLP-1 RAs from DPP-4 inhibitors and from insulin
6. Compare and contrast short- and long-acting GLP-1 RAs.

Accreditation and credit designation statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME), The American College of Osteopathic Family Physicians (ACOFP), and E&S MedEd Group, Inc. The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians.

The EOCME designates this enduring material for a maximum of 2.0 *AMA PRA Category 1 Credit(s)*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ACOFP is accredited by the American Osteopathic Association (AOA) to sponsor continuing medical education (CME) for osteopathic physicians. The ACOFP designates podium lectures and interactive workshops for category 1-A credit on an hour-for-hour basis. This program is sponsored by the ACOFP for educational purposes only. The material is not intended to represent the sole or the best medical intervention(s) for the discussed diagnoses, but rather is intended to present the opinions of the authors or presenters that may be helpful to other practitioners. Attendees participating in this medical education program do so with the full knowledge that they waive any claim they may have against the ACOFP for reliance on any information presented during these educational activities.

ACOFP designates this enduring activity for a maximum of 2.0 hours of Category 1-A CME credits for osteopathic family physicians.

CME planning committee

Jeffrey S. Freeman, DO, FACOI
James R. LaSalle, DO
Frank Lavernia, MD
Laurie Ermentrout
Kate Mann, PharmD
Sandy Breslow
Ken Korber
Jill McNair

This activity is jointly sponsored by



This activity is supported by an educational grant from Novo Nordisk Inc.

Method of participation

There are no fees for participating and receiving CME credit for this activity. In order to receive credit for completing this activity, participants must:

1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of the activity.
2. Read the content of the supplement.
3. Complete the online posttest and evaluation or mail/fax the printed posttest/evaluation to the address listed above.
4. Physicians who receive a grade of 70% or better on the posttest and who complete the evaluation will receive a CME certificate.
5. All other participants who receive a grade of 70% or better on the posttest and who complete the evaluation will receive a certificate of participation.

Disclosure information

As a sponsor accredited by the ACCME, it is the policy of the EOCME to require the disclosure of anyone who is in a position to control the content of an educational activity. All relevant financial relationships with any commercial interests or manufacturers or both must be disclosed to participants at the beginning of each activity. The faculty and planning committee of this educational activity discloses the following:

Jeffrey S. Freeman, DO, FACOI

Professor and Chairman
Division of Endocrinology and Metabolism
Department of Internal Medicine
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania

Disclosures:

Consultant, advisor: Novo Nordisk Inc
Speakers' Bureau: Bristol-Myers Squibb, tsk Medical Co, Boehringer Ingelheim, Eli Lilly and Company, Amylin Pharmaceuticals, Inc, Lis Scan, and AstraZeneca.

James R. LaSalle, DO

Medical Director
Medical Arts Research Collaborative
Excelsior Springs, Missouri

Disclosures:

Speakers' Bureau: Novo Nordisk Inc, Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline, and AstraZeneca.
Consultant, advisor: Novo Nordisk Inc, AstraZeneca, and GlaxoSmithKline
Research grant: AstraZeneca.

Frank Lavernia, MD

Director, North Broward Diabetes Center
Pompano Beach, Florida

Disclosures:

Speakers' Bureau: Abbott Pharmaceuticals, Novo Nordisk Inc.

Vincent Friedewald, JR, MD

Conflict of Interest Reviewer

Disclosures: has no relevant financial disclosures.

Laurie Ermentrout

Planning committee staff

Disclosures: has no relevant financial disclosures.

Kate Mann, PharmD

Planning committee staff

Disclosures: has no relevant financial disclosures.

Sandy Breslow

Planning committee staff

Disclosures: has no relevant financial disclosures.

Ken Korber

Planning committee staff

Disclosures: has no relevant financial disclosures.

Jill McNair

Planning committee staff

Disclosures: has no relevant financial disclosures.

Resolution of conflict of interest

The EOCME has implemented a process to resolve conflict of interest for each CME activity. In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interests of the public, the EOCME has resolved the conflict by external content review.

Unapproved/Off-label use disclosure

(1) When products or procedures being discussed are off-label, unlabeled, experimental, and investigational (not US Food and Drug Administration [FDA] approved); and (2) Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labeling. This information is intended solely for CME and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

CME inquiries

For all CME certificate inquiries, please contact us at elsevierCME@elsevier.com.

Special needs

We encourage participation by all individuals. If you have any special needs, please contact us at elsevierCME@elsevier.com.

Release date of activity: January 15, 2013

Expiration date of activity for AMA PRA credit: January 14, 2014

Expiration date of activity for Category 1-A CME credit for osteopathic physicians: January 14, 2014

Estimated time to complete this activity: 2.0 hours